Cobenfy(KarXT)怎么购买

Cobenfy (KarXT) is a new oral compound preparation, whose ingredients include xanomeline (central muscarinic agonist) and trospiumchloride (peripheral muscarinic antagonist).

How to buy Cobenfy(KarXT)

It is a prescription drug and cannot be purchased by yourself. Patients must be fully evaluated by a psychiatrist and confirmed to meet the indications (adult schizophrenia) and have no contraindications (such as urinary retention, moderate to severe liver damage, etc.) before a prescription can be issued.

Patients can obtain it with a prescription at hospital pharmacies or authorized pharmacies that cooperate with drug dealers. The drug is currently on the market in the United States. Please pay attention to the announcements from local drug regulatory agencies for the listing status in other countries or regions.

Since Cobenfy is a strictly controlled prescription drug and requires individual dosage adjustment, it is not recommended to purchase it through informal channels to avoid risks caused by improper medication.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Common adverse reactions of Cobenfy (KarXT)

In clinical trials, adverse reactions that occurred in ≥5% of patients and were more than 2 times higher than placebo include:

1. Digestive system: nausea (19%), indigestion (18%), constipation (17%), vomiting (15%), abdominal pain (8%), diarrhea (6%).

2. Cardiovascular system: hypertension (11%), tachycardia (5%).

3. Nervous system: dizziness (5%).

4. Others: gastroesophageal reflux disease (5%).

In addition, some patients may experience urinary retention, elevated liver enzymes, blurred vision, dry mouth, drowsiness or hallucinations, etc., and require close observation.

Precautions for the use of Cobenfy (KarXT)

1. Contraindicated groups

The following patients are prohibited from using Cobenfy:

(1) Those with a history of urinary or gastric retention.

(2) Those with moderate or severe liver dysfunction.

(3) Those who are allergic to xanomeline or trospium chloride.

(4) Patients with untreated narrow-angle glaucoma.

2. Medication recommendations for special groups

(1) Elderly people: It is recommended to start with a low dose and adjust slowly, with the maximum dose not exceeding 100mg/20mg, twice a day.

(2) People with liver/kidney dysfunction: Not recommended for use with moderate to severe liver damage or kidney damage (eGFR <60mL/min); use with caution with mild liver damage.

(3) Pregnant and lactating women: There is currently a lack of human data, and the benefits and risks should be evaluated before use.

3. Monitoring and examination items

Liver enzymes, bilirubin and heart rate should be monitored before and during treatment. If you have difficulty urinating, abdominal pain, jaundice, palpitations, facial or throat swelling, etc., you should seek medical attention immediately.

4. Drug interactions

(1) Avoid co-administration with strong CYP2D6 inhibitors (such as paroxetine), which may increase the plasma concentration of xanomeline.

(2) Combination with other anticholinergic drugs may increase side effects such as dry mouth and constipation.

(3). It may affect renal tubular secretion or metabolism of CYP3A4/P-gp substrate drugs, so the dose needs to be adjusted or monitoring strengthened.

5. Driving and operating machinery

Cobenfy may cause dizziness, drowsiness or blurred vision. You should avoid driving or operating heavy machinery during medication until individual reactions are clear.